ELEVATE phase 2 trial
Elacestrant combined with everolimus or abemaciclib provides meaningful PFS in ER+/HER2โ metastatic breast cancer (8.3 and 14.3 months).
Both combinations had expected, manageable safety with no new signals.
Elacestrant may become a key oral ET backbone for future combination strategies.
#SABCS25
@OncoAlert